Table 1 Key characteristics at baseline of individuals included in the study
Characteristic | BC diagnosis by end of follow-up | All | |
|---|---|---|---|
Yes | No | ||
Number | 518 | 39,569 | 40,087 |
   Invasive | 443 (85.5%) | – | – |
   In-situ | 75 (14.5%) | – | – |
   Screen detected | 374 (72.2%) | – | – |
   Symptomatic | 144 (27.8%) | – | – |
No. of screens | Â | Â | Â |
   2 rounds | 317 (61.2%) | 9210 (23.3%) | 9527 (23.7%) |
   3 rounds | 176 (34.0%) | 24,832 (62.7%) | 25,008 (62.4%) |
   4 rounds | 25 (4.8%) | 5418 (13.7%) | 5443 (13.6%) |
   5 or 6 rounds | – | 109 (0.3%) | 109 (0.3%) |
MHT use | Â | Â | Â |
   Never | 387 (74.7%) | 32,513 (82.2%) | 32,900 (82.1%) |
   Past | 96 (18.5%) | 5608 (14.2%) | 5704 (14.2%) |
   Current | 35 (6.7%) | 1448 (3.6%) | 1483 (3.7%) |
Age at baseline | 57 (9.4) | 53.5 (9.3) | 53.5 (9.3) |
BMI | 25.5 (4.1) | 25.1 (4.1) | 25.2 (4.2) |
sqrt(MD) | 5 (2.3) | 4.8 (2.3) | 4.8 (2.3) |
MP status | Â | Â | Â |
   Pre | 191 (36.9%) | 19,285 (47.7%) | 19,476 (48.6%) |
   Post | 327 (63.1%) | 20,284 (51.3%) | 20,611 (51.4%) |
FH | Â | Â | Â |
   Yes | 112 (21.6%) | 5249 (13.3%) | 5361 (13.4%) |
   No | 392 (75.7%) | 33,290 (84.1%) | 33,682 (84.0 %) |
   Missing | 14 (2.7%) | 1030 (2.6%) | 1044 (2.6%) |